Metabolic associated liver disease

被引:1
|
作者
Testino, Gianni [1 ,3 ]
Pellicano, Rinaldo [2 ]
机构
[1] Polyclin San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O, Genoa, Italy
[2] Molinette SGAS Hosp, Unit Gastroenterol, Turin, Italy
[3] Polyclin San martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O Padigl 10,Piazzale R Benzi 10, I-16132 Genoa, Italy
关键词
Alcohol drinking; Metabolic syndrome; Non-alcoholic fatty liver disease; Diabetes mellitus; type; 2; NONALCOHOLIC FATTY LIVER; ALCOHOL-USE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BLOOD-PRESSURE; FIBROSIS; RISK; IDENTIFICATION; PERFORMANCE; MANAGEMENT;
D O I
10.23736/S0031-0808.22.04730-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In real practice the patient with liver disease is often the carrier of multiple etiological factors such as metabolic syndrome (MS) and alcohol consumption (AC). Their copresence is often underestimated and AC is not adequately studied. Traditionally to diagnose non-alcoholic fatty liver disease (NAFLD), AC must not exceed 30 gr for men and 20 gr for women per day. This limit should still be reduced, especially in relation to the AC and fibrogenesis ratio and also frequent misestimation of AC or unrecognized MS may underestimate multi caused liver injury. AC is a contributing cause of MS and alcoholic and non-alcoholic liver disease have a substantially overlapping histopathological picture. Moreover, AC and MS are cause and contributing cause of extra-hepatic morbidity and mortality. It can be concluded that the possible simplification of terminology at metabolic associated liver disease (MALD) makes clinical activity more usable and immediate, facilitates better communication and cooperation between scientific societies and specialists who apparently deal with different medical sectors, facilitates early identification of related hepatic and extra-hepatic pathology, allows to "see the person in a unitary way," to create more streamlined care pathways, to reduce the hospitalization rate with relative cost-benefit advantage and to create unitary prevention and health promotion policies.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [21] Macrophages in metabolic associated fatty liver disease
    Alharthi, Jawaher
    Latchoumanin, Olivier
    George, Jacob
    Eslam, Mohammed
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (16) : 1861 - 1878
  • [22] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [23] Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)
    Canivet, C. M.
    Faure, S.
    REVUE DE MEDECINE INTERNE, 2024, 45 (01): : 41 - 47
  • [24] The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease
    Lee, Hye Won
    Kim, Kun Hee
    Ahn, Sang Hoon
    Lee, Han Chu
    Choi, Jonggi
    LIVER INTERNATIONAL, 2024, 44 (06) : 1448 - 1455
  • [25] Management of metabolic-associated fatty liver disease: The diabetology perspective
    Jeeyavudeen, Mohammad Sadiq
    Khan, Shahanas K. A.
    Fouda, Sherouk
    Pappachan, Joseph M.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (01) : 126 - 143
  • [26] Management of fatty liver disease with the metabolic syndrome
    Machado, Mariana Verdelho
    Cortez-Pinto, Helena
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (05) : 487 - 500
  • [27] Metabolic syndrome, non-alcoholic fatty liver disease, and hepatocellular carcinoma
    Serradilla Martin, Mario
    Oliver Guillen, Jose Ramon
    Palomares Cano, Ana
    Ramia Angel, Jose Manuel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (02) : 133 - 138
  • [28] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [29] Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients
    Ortolan, Augusta
    Lorenzin, Mariagrazia
    Tadiotto, Giulia
    Russo, Francesco Paolo
    Oliviero, Francesca
    Felicetti, Mara
    D'Inca, Renata
    Favero, Marta
    Piaserico, Stefano
    Doria, Andrea
    Ramonda, Roberta
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2843 - 2850
  • [30] Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study
    Gosnell, Joseph Matthew
    Golovko, George
    Arroyave, Esteban
    Moghe, Akshata
    Kueht, Michael L.
    Saldarriaga, Omar Abdul
    Mckinney, Kevin H.
    Stevenson, Heather L.
    Ferguson, Monique R.
    WORLD JOURNAL OF DIABETES, 2024, 15 (05)